Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-21-143012
Filing Date
2021-04-30
Accepted
2021-04-30 09:58:48
Documents
6
Effectiveness Date
2021-04-30

Document Format Files

Seq Description Document Type Size
1 S-8 d173231ds8.htm S-8 61600
2 EX-5.1 d173231dex51.htm EX-5.1 8484
3 EX-23.1 d173231dex231.htm EX-23.1 2073
4 GRAPHIC g173231dsp012.jpg GRAPHIC 2037
5 GRAPHIC g173231dsp012a.jpg GRAPHIC 2357
6 GRAPHIC g173231dsp012b.jpg GRAPHIC 6083
  Complete submission text file 0001193125-21-143012.txt   88054
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-255636 | Film No.: 21874379
SIC: 2834 Pharmaceutical Preparations